MedTrace Logo

To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets

NCT00913419 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of Cyclobenzaprine HCl tablets.

Conditions

Interventions

DRUG

Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories

DRUG

Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme

Sponsors & Collaborators

Principal Investigators

  • A. Orson Brod, M.D. · PharmaKineticsLaboratories, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1988-11-30
Primary Completion
1988-12-31
Completion
1988-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913419 on ClinicalTrials.gov